Browse > Article
http://dx.doi.org/10.4142/jvs.2021.22.e61

Arginase-1 and P-glycoprotein are downregulated in canine hepatocellular carcinoma  

Kim, Soo-Hyeon (Department of Veterinary Pathology, Small Animal Diagnostic Center, College of Veterinary Medicine, Konkuk University)
Seung, Byung-Joon (Department of Veterinary Pathology, Small Animal Diagnostic Center, College of Veterinary Medicine, Konkuk University)
Cho, Seung-Hee (Department of Veterinary Pathology, Small Animal Diagnostic Center, College of Veterinary Medicine, Konkuk University)
Lim, Ha-Young (Department of Veterinary Pathology, Small Animal Diagnostic Center, College of Veterinary Medicine, Konkuk University)
Bae, Min-Kyung (Department of Veterinary Pathology, Small Animal Diagnostic Center, College of Veterinary Medicine, Konkuk University)
Sur, Jung-Hyang (Department of Veterinary Pathology, Small Animal Diagnostic Center, College of Veterinary Medicine, Konkuk University)
Publication Information
Journal of Veterinary Science / v.22, no.5, 2021 , pp. 61.1-61.13 More about this Journal
Abstract
Background: Hepatocellular carcinoma is the most common primary hepatic malignancy in humans and dogs. Several differentially expressed molecules have been studied and reported in human hepatocellular carcinoma and non-neoplastic liver lesions. However, studies on the features of canine hepatocellular carcinoma are limited, especially related to the differential characteristics of neoplastic and non-neoplastic lesions. Objectives: The study's objective was 1) to examine and evaluate the expression of arginase-1, P-glycoprotein, and cytokeratin 19 in canine liver tissues and 2) to investigate the differential features of hepatocellular carcinomas, liver tissue with non-neoplastic lesions, and paracancerous liver tissues in dogs. Methods: The expression levels of three markers underwent immunohistochemical analysis in 40 non-neoplastic liver tissues, 32 hepatocellular carcinoma tissues, and 11 paracancerous liver tissues. Scoring of each marker was performed semi-quantitatively. Results: Arginase-1 and P-glycoprotein were significantly downregulated in hepatocellular carcinoma, compared with hepatic tissues with non-neoplastic diseases (p < 0.001). Expression levels of arginase-1 and P-glycoprotein were also significantly lower in hepatocellular carcinoma than in paracancerous liver tissues (arginase-1, p = 0.0195; P-glycoprotein, p = 0.047). Few cytokeratin 19-positive hepatocytes were detected and only in one hepatocellular carcinoma and one cirrhotic liver sample. Conclusions: The results of this study suggest that downregulation of arginase-1 and P-glycoprotein is a feature of canine hepatocellular carcinoma; thus, those markers are potential candidates for use in differentiating hepatocellular carcinomas from non-neoplastic liver lesions in dogs.
Keywords
Arginase; dog; hepatocellular carcinoma; liver; P-glycoprotein;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Hirose N, Uchida K, Kanemoto H, Ohno K, Chambers JK, Nakayama H. A retrospective histopathological survey on canine and feline liver diseases at the University of Tokyo between 2006 and 2012. J Vet Med Sci. 2014;76(7):1015-1020.   DOI
2 Vascellari M, Baioni E, Ru G, Carminato A, Mutinelli F. Animal tumour registry of two provinces in northern Italy: incidence of spontaneous tumours in dogs and cats. BMC Vet Res. 2009;5(1):39.   DOI
3 Van den ingh TSGAM, Van winkle T, Cullen JM, Charles JA, Desmet VJ. 2006. Morphological classification of parenchymal disorders of the canine and feline liver. In: Rothuizen J, Bunch SE, Charles JA, Cullen JM, Desmet VJ, Szatmari V, et al. editors. WSAVA Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Disease. Amsterdam: W.B. Saunders Company; 2006, 85-99.
4 Hewitt SM, Baskin DG, Frevert CW, Stahl WL, Rosa-Molinar E. Controls for immunohistochemistry: the Histochemical Society's standards of practice for validation of immunohistochemical assays. J Histochem Cytochem. 2014;62(10):693-697.   DOI
5 You J, Chen W, Chen J, Zheng Q, Dong J, Zhu Y. The oncogenic role of ARG1 in progression and metastasis of hepatocellular carcinoma. BioMed Res Int. 2018;2018:2109865.   DOI
6 Kong XB, Yang ZK, Liang LJ, Huang JF, Lin HL. Overexpression of P-glycoprotein in hepatocellular carcinoma and its clinical implication. World J Gastroenterol. 2000;6(1):134-135.   DOI
7 Namisaki T, Schaeffeler E, Fukui H, Yoshiji H, Nakajima Y, Fritz P, et al. Differential expression of drug uptake and efflux transporters in Japanese patients with hepatocellular carcinoma. Drug Metab Dispos. 2014;42(12):2033-2040.   DOI
8 Ng IO, Liu CL, Fan ST, Ng M. Expression of P-glycoprotein in hepatocellular carcinoma. A determinant of chemotherapy response. Am J Clin Pathol. 2000;113(3):355-363.   DOI
9 Jain R, Fischer S, Serra S, Chetty R. The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. Appl Immunohistochem Mol Morphol. 2010;18(1):9-15.   DOI
10 Quaglia A. Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist. J Hepatocell Carcinoma. 2018;5:99-108.   DOI
11 van Sprundel RG, van den Ingh TS, Desmet VJ, Katoonizadeh A, Penning LC, Rothuizen J, et al. Keratin 19 marks poor differentiation and a more aggressive behaviour in canine and human hepatocellular tumours. Comp Hepatol. 2010;9(1):4.   DOI
12 Ramakrishna G, Rastogi A, Trehanpati N, Sen B, Khosla R, Sarin SK. From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer. 2013;2(3- 4):367-383.   DOI
13 Liptak JM, Dernell WS, Monnet E, Powers BE, Bachand AM, Kenney JG, et al. Massive hepatocellular carcinoma in dogs: 48 cases (1992-2002). J Am Vet Med Assoc. 2004;225(8):1225-1230.   DOI
14 Feng J, Zhu R, Chang C, Yu L, Cao F, Zhu G, et al. CK19 and glypican 3 expression profiling in the prognostic indication for patients with hepatocellular carcinoma after surgical resection. PLoS One. 2016;11(3):e0151501.   DOI
15 Uenishi T, Kubo S, Yamamoto T, Shuto T, Ogawa M, Tanaka H, et al. Cytokeratin 19 expression in hepatocellular carcinoma predicts early postoperative recurrence. Cancer Sci. 2003;94(10):851-857.   DOI
16 van Sprundel RG, van den Ingh TS, Guscetti F, Kershaw O, Kanemoto H, van Gils HM, et al. Classification of primary hepatic tumours in the dog. Vet J. 2013;197(3):596-606.   DOI
17 Vatnikov Y, Vilkovysky I, Kulikov E, Popova I, Khairova N, Gazin A, et al. Size of canine hepatocellular carcinoma as an adverse prognostic factor for surgery. J Adv Vet Anim Res. 2020;7(1):127-132.   DOI
18 Charles JA, Cullen JM, Van den ingh TSGAM, Van winkle T, Desmet VJ. Morphological classification of neoplastic disorders of the canine and feline liver. In: Rothuizen J, Bunch SE, Charles JA, Cullen JM, Desmet VJ, Szatmari V, et al. editors. WSAVA Standards for Clinical and Histological Diagnosis of Canine and Feline Liver Disease. Amsterdam: W.B. Saunders Company; 2006, 117-124.
19 Ringelhan M, McKeating JA, Protzer U. Viral hepatitis and liver cancer. Philos Trans R Soc Lond B Biol Sci. 2017;372(1732):20160274.   DOI
20 Govaere O, Petz M, Wouters J, Vandewynckel YP, Scott EJ, Topal B, et al. The PDGFRα-laminin B1-keratin 19 cascade drives tumor progression at the invasive front of human hepatocellular carcinoma. Oncogene. 2017;36(47):6605-6616.   DOI
21 Sykes JE. Infectious Canine Hepatitis. Canine and Feline Infectious Diseases. St. Louis: Elsevier/Saunders; 2014, 182-186.
22 Ginn PE. Immunohistochemical detection of P-glycoprotein in formalin-fixed and paraffin-embedded normal and neoplastic canine tissues. Vet Pathol. 1996;33(5):533-541.   DOI
23 Geramizadeh B, Seirfar N. Diagnostic value of arginase-1 and glypican-3 in differential diagnosis of hepatocellular carcinoma, cholangiocarcinoma and metastatic carcinoma of liver. Hepat Mon. 2015;15(7):e30336.
24 Cao W, Sun B, Feitelson MA, Wu T, Tur-Kaspa R, Fan Q. Hepatitis C virus targets over-expression of arginase I in hepatocarcinogenesis. Int J Cancer. 2009;124(12):2886-2892.   DOI
25 Hepatitis [Internet]. Treasure Island (FL): StatPearls Publishing; https://www.ncbi.nlm.nih.gov/books/NBK554549. Updated 2021. Accessed 2021 May 21.
26 Zamor PJ, deLemos AS, Russo MW. Viral hepatitis and hepatocellular carcinoma: etiology and management. J Gastrointest Oncol. 2017;8(2):229-242.   DOI
27 Moudi B, Mahmoudzadeh-Sagheb H, Heidari Z. Hepatocyte paraffin 1 and arginase-1 are effective panel of markers in HBV-related HCC diagnosis in fine-needle aspiration specimens. BMC Res Notes. 2020;13(1):388.   DOI
28 Yan BC, Gong C, Song J, Krausz T, Tretiakova M, Hyjek E, et al. Arginase-1: a new immunohistochemical marker of hepatocytes and hepatocellular neoplasms. Am J Surg Pathol. 2010;34(8):1147-1154.   DOI
29 Kemp SD, Zimmerman KL, Panciera DL, Monroe WE, Leib MS. Histopathologic variation between liver lobes in dogs. J Vet Intern Med. 2015;29(1):58-62.   DOI
30 Cole TL, Center SA, Flood SN, Rowland PH, Valentine BA, Warner KL, et al. Diagnostic comparison of needle and wedge biopsy specimens of the liver in dogs and cats. J Am Vet Med Assoc. 2002;220(10):1483-1490.   DOI
31 Sanai FM, Keeffe EB. Liver biopsy for histological assessment: The case against. Saudi J Gastroenterol. 2010;16(2):124-132.   DOI
32 Toth K, Vaughan MM, Peress NS, Slocum HK, Rustum YM. MDR1 P-glycoprotein is expressed by endothelial cells of newly formed capillaries in human gliomas but is not expressed in the neovasculature of other primary tumors. Am J Pathol 1996;149(3):853-858.
33 Caldwell RW, Rodriguez PC, Toque HA, Narayanan SP, Caldwell RB. Arginase: a multifaced enzyme important in health and disease. Physiol Rev. 2018;98(2):641-665.   DOI
34 Vander Borght S, Komuta M, Libbrecht L, Katoonizadeh A, Aerts R, Dymarkowski S, et al. Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int. 2008;28(10):1370-1380.   DOI
35 Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science. 2015;347(6220):1260419.   DOI
36 Tashbaeva RE, Hwang DN, Song GS, Choi NH, Lee JH, Lyoo YS, et al. Cellular characterization of multidrug resistance P-glycoprotein, alpha fetoprotein, and neovascular endothelium-associated antigens in canine hepatocellular carcinoma and cirrhotic liver. Vet Pathol. 2007;44(5):600-606.   DOI
37 Patnaik AK, Hurvitz AI, Lieberman PH. Canine hepatic neoplasms: a clinicopathologic study. Vet Pathol. 1980;17(5):553-564.   DOI
38 Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47 Suppl:S2-S6.   DOI
39 Takanishi K, Miyazaki M, Ohtsuka M, Nakajima N. Inverse relationship between P-glycoprotein expression and its proliferative activity in hepatocellular carcinoma. Oncology. 1997;54(3):231-237.   DOI
40 Partridge BR, O'Brien TJ, Lorenzo MF, Coutermarsh-Ott SL, Barry SL, Stadler K, et al. High-frequency irreversible electroporation for treatment of primary liver cancer: a proof-of-principle study in canine hepatocellular carcinoma. J Vasc Interv Radiol. 2020;31(3):482-491.e4.   DOI
41 Radwan NA, Ahmed NS. The diagnostic value of arginase-1 immunostaining in differentiating hepatocellular carcinoma from metastatic carcinoma and cholangiocarcinoma as compared to HepPar-1. Diagn Pathol. 2012;7(1):149.   DOI
42 Staud F, Ceckova M, Micuda S, Pavek P. Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol Biol. 2010;596:199-222.   DOI
43 Hodges LM, Markova SM, Chinn LW, Gow JM, Kroetz DL, Klein TE, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011;21(3):152-161.   DOI
44 Zollner G, Wagner M, Fickert P, Silbert D, Fuchsbichler A, Zatloukal K, et al. Hepatobiliary transporter expression in human hepatocellular carcinoma. Liver Int. 2005;25(2):367-379.   DOI
45 Kowalik MA, Sulas P, Ledda-Columbano GM, Giordano S, Columbano A, Perra A. Cytokeratin-19 positivity is acquired along cancer progression and does not predict cell origin in rat hepatocarcinogenesis. Oncotarget. 2015;6(36):38749-38763.   DOI
46 Vilkovyskiy IF, Vatnikov YA, Kulikov EV, Sotnikova ED, Yagnikov SA, Seleznev SB, et al. Influence of hepatic neoplasia on life expectancy in dogs. Vet World. 2020;13(3):413-418.   DOI
47 Dimitroulis D, Damaskos C, Valsami S, Davakis S, Garmpis N, Spartalis E, et al. From diagnosis to treatment of hepatocellular carcinoma: an epidemic problem for both developed and developing world. World J Gastroenterol. 2017;23(29):5282-5294.   DOI